Zurcher Kantonalbank Zurich Cantonalbank Sells 26,969 Shares of Encompass Health Co. (NYSE:EHC)

Zurcher Kantonalbank Zurich Cantonalbank decreased its position in Encompass Health Co. (NYSE:EHCFree Report) by 3.8% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 673,628 shares of the company’s stock after selling 26,969 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank owned approximately 0.67% of Encompass Health worth $65,099,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Magnetar Financial LLC lifted its holdings in shares of Encompass Health by 1,176.6% during the 2nd quarter. Magnetar Financial LLC now owns 744,836 shares of the company’s stock valued at $63,899,000 after purchasing an additional 814,018 shares in the last quarter. Thrivent Financial for Lutherans raised its holdings in shares of Encompass Health by 2,302.7% during the second quarter. Thrivent Financial for Lutherans now owns 603,558 shares of the company’s stock worth $51,780,000 after acquiring an additional 578,438 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Encompass Health by 614.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 540,519 shares of the company’s stock worth $44,637,000 after purchasing an additional 464,897 shares during the period. AQR Capital Management LLC increased its holdings in Encompass Health by 213.3% during the 2nd quarter. AQR Capital Management LLC now owns 207,202 shares of the company’s stock worth $17,776,000 after purchasing an additional 141,075 shares in the last quarter. Finally, Cubist Systematic Strategies LLC lifted its holdings in shares of Encompass Health by 762.4% in the second quarter. Cubist Systematic Strategies LLC now owns 83,347 shares of the company’s stock valued at $7,150,000 after purchasing an additional 73,683 shares in the last quarter. Institutional investors and hedge funds own 97.25% of the company’s stock.

Encompass Health Price Performance

NYSE:EHC opened at $102.84 on Thursday. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. The firm has a market capitalization of $10.36 billion, a price-to-earnings ratio of 24.84, a P/E/G ratio of 1.35 and a beta of 0.88. Encompass Health Co. has a 12-month low of $63.78 and a 12-month high of $104.55. The stock’s 50 day moving average price is $97.53 and its two-hundred day moving average price is $91.11.

Encompass Health (NYSE:EHCGet Free Report) last released its quarterly earnings data on Monday, October 28th. The company reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.09. The firm had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.33 billion. Encompass Health had a net margin of 8.10% and a return on equity of 17.60%. The company’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.86 earnings per share. On average, analysts anticipate that Encompass Health Co. will post 4.29 earnings per share for the current year.

Encompass Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Thursday, January 2nd will be given a dividend of $0.17 per share. The ex-dividend date is Thursday, January 2nd. This represents a $0.68 annualized dividend and a yield of 0.66%. Encompass Health’s dividend payout ratio (DPR) is presently 16.43%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. KeyCorp lifted their target price on Encompass Health from $115.00 to $117.00 and gave the company an “overweight” rating in a research report on Tuesday, October 29th. Truist Financial reiterated a “buy” rating and issued a $116.00 price objective (up from $108.00) on shares of Encompass Health in a report on Wednesday, October 30th. UBS Group raised their target price on shares of Encompass Health from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Barclays boosted their price target on shares of Encompass Health from $109.00 to $116.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 29th. Finally, Stephens restated an “overweight” rating and issued a $105.00 price objective on shares of Encompass Health in a report on Tuesday, August 6th. Nine investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Encompass Health currently has an average rating of “Buy” and an average target price of $107.11.

Read Our Latest Report on Encompass Health

Encompass Health Company Profile

(Free Report)

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.

Further Reading

Want to see what other hedge funds are holding EHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Encompass Health Co. (NYSE:EHCFree Report).

Institutional Ownership by Quarter for Encompass Health (NYSE:EHC)

Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.